Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 29;10(13):2905. doi: 10.3390/jcm10132905

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The effect of type TNF-α inhibitor used on serum levels of bone turnover markers, i.e. PINP (a), CTX-I (b) and osteoclastogenesis markers: sRANKL (c) and OPG (d) in female rheumatoid arthritis patients during 15-month therapy. ^a* p < 0.01 or ^a** p < 0.001 compared to the baseline. ADA, adalimumab; CTX-I, C-terminal cross-linking telopeptides of type I collagen; ETA, etanercept; OPG, osteoprotegerin; PINP, N-terminal propeptides of type I procollagen; RA, rheumatoid arthritis; sRANKL, total soluble receptor activator of nuclear factor κB ligand; TNFαI, tumor necrosis factor α inhibitors.

The effect of type TNF-α inhibitor used on serum levels of bone turnover markers, i.e. PINP (a), CTX-I (b) and osteoclastogenesis markers: sRANKL (c) and OPG (d) in female rheumatoid arthritis patients during 15-month therapy. ^a* p < 0.01 or ^a** p < 0.001 compared to the baseline. ADA, adalimumab; CTX-I, C-terminal cross-linking telopeptides of type I collagen; ETA, etanercept; OPG, osteoprotegerin; PINP, N-terminal propeptides of type I procollagen; RA, rheumatoid arthritis; sRANKL, total soluble receptor activator of nuclear factor κB ligand; TNFαI, tumor necrosis factor α inhibitors.